Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding

Launched by UNIVERSITY OF HEALTH SCIENCES LAHORE · Jan 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether calcium dobesilate can help treat heavy menstrual bleeding, also known as menorrhagia, in women aged 18 to 39 years. The researchers want to find out if calcium dobesilate works as well as tranexamic acid, which is a common treatment for this condition. They will look at how much menstrual blood loss is reduced and if hemoglobin levels—important for overall health—improve with either medication. Additionally, they will compare any side effects and how acceptable each treatment is to the participants.

To participate, women must be between 18 and 39 years old and experience heavy menstrual bleeding. They should not have certain health conditions, like very low hemoglobin levels or specific pelvic disorders. During the trial, participants will take either calcium dobesilate or tranexamic acid for three menstrual cycles and will keep track of their bleeding using a simple chart. They will also have follow-up visits to check their hemoglobin levels and any symptoms or side effects they may experience. This trial is not yet recruiting participants, but it aims to provide valuable information about alternative treatments for heavy menstrual bleeding.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients age 18 to 39 years
• • 2. Patients with menorrhagia
• • 3. Incidence of breakthrough bleeding while on treatment
• • 4. Patient with heaviness of the bleeding
• Exclusion Criteria:
• • 1. Patients with hemoglobin less than 7gm/dl
• • 2. Patient with pelvic pathologies like uterine fibroids, suspected adenomyosis, malignancies of uterus/cervix/ovary/vagina/endometrial hyperplasia with atypia.
• • 3. Patient with medical diseases like liver dysfunction, heart disease, migraine, stroke, renal disease, hypo/hyperthyroidism, platelet disorders or coagulopathy.
• • 4. Patient with previous history of thrombosis; pregnancy, abortion, use of IUCDs or oral contraceptives; lactating women in first 6 months of post-natal period and hypersensitivity to the drug